66,900 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Bayesian Capital Management LP

Bayesian Capital Management LP bought a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 66,900 shares of the company’s stock, valued at approximately $452,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Barclays PLC raised its stake in Recursion Pharmaceuticals by 53.9% during the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock worth $4,596,000 after acquiring an additional 244,278 shares during the period. JPMorgan Chase & Co. raised its position in shares of Recursion Pharmaceuticals by 6.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock worth $7,751,000 after purchasing an additional 67,464 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Green Alpha Advisors LLC boosted its position in Recursion Pharmaceuticals by 3.6% during the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock valued at $454,000 after purchasing an additional 2,346 shares during the period. Finally, DBK Financial Counsel LLC bought a new position in Recursion Pharmaceuticals during the 4th quarter worth $101,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $4.16 on Wednesday. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The firm has a market cap of $1.67 billion, a P/E ratio of -2.72 and a beta of 0.99. The stock has a fifty day moving average price of $5.68 and a two-hundred day moving average price of $6.71. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same period in the prior year, the business earned ($0.39) EPS. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Morgan Stanley dropped their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Needham & Company LLC reduced their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Leerink Partners reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.60.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.